Immunic(US:IMUX)2026-03-18 17:02Summary of Immunic Conference Call Company Overview - Company: Immunic - Key Product: Vidofludimus calcium, a drug in development for treating multiple sclerosis (MS) Industry Context - Market: Multiple Sclerosis (MS) treatment landscape, which includes various therapies with differing safety and efficacy profiles Key Points 2026 Outlook - 2026 is expected to be transformative for Immunic with the phase 3 readout of ENSURE-1 and ENSURE-2 studies planned for the end of the year [1] - NDA submission for vidofludimus calcium is planned for the following year [1] Drug Mechanism and Safety Profile - Vidofludimus calcium is designed as a safer and more selective DHODH inhibitor compared to Aubagio, avoiding off-target activities that lead to side effects [3][4] - The drug activates the nuclear receptor Nurr1, providing neuroprotective effects and solid anti-inflammatory activity [3][7] - Safety data indicates that vidofludimus calcium has a favorable liver toxicity profile compared to teriflunomide, with liver enzyme elevations comparable to placebo [10] - The elimination half-life of vidofludimus calcium is approximately 30 hours, allowing for quicker clearance compared to teriflunomide, which has a half-life of 10-19 days [11] Clinical Data and Efficacy - In the EMPhASIS study, vidofludimus calcium showed a 57% lower rate of confirmed disability progression compared to the control group [13] - The CALLIPER study indicated a 31% reduction in confirmed disability worsening in primary progressive MS (PPMS) patients [16] - The primary endpoint for upcoming studies will be time to first relapse, with secondary endpoints including confirmed disability progression and improvement [20] Market Positioning - Vidofludimus calcium aims to capture the oral medication segment, which constitutes 35%-40% of all prescriptions in the U.S. for MS [26] - The drug is positioned to address unmet needs in patients transitioning from CD20 therapies, which have serious infection risks [30] - The company believes that vidofludimus calcium will offer a best-in-class benefit-risk profile, particularly for patients preferring oral administration [27] Future Plans - A confirmatory study for PPMS is expected to start in the second half of the year, with an estimated duration of 3.5-4 years for enrollment and data readout [38] - The company anticipates significant market potential, estimating a multi-billion dollar upside for the PPMS indication [41] Conclusion - Immunic is optimistic about the upcoming data and believes that vidofludimus calcium could provide a new treatment option for individuals living with MS, addressing both relapsing and progressive forms of the disease [40][41]